Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non‑small cell lung cancer cells to SN‑38 and 5‑FU 
without alteration to p53 expression levels

Yan,Dongmei; Zheng,Xiaoliang; Tu,Linglan; Jia,Jing; Li,Qin; Cheng,Liyan; Wang,Xiaoju

doi:10.3892/mmr.2014.2764

Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non‑small cell lung cancer cells to SN‑38 and 5‑FU without alteration to p53 expression levels

Authors:
- Dongmei Yan
- Xiaoliang Zheng
- Linglan Tu
- Jing Jia
- Qin Li
- Liyan Cheng
- Xiaoju Wang
View Affiliations

Affiliations: Center for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, P.R. China, Institute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, P.R. China
Published online on: October 24, 2014 https://doi.org/10.3892/mmr.2014.2764
Pages: 295-302

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Merm1/Wbscr22 is a novel metastasis promoter that has been shown to be involved in tumor metastasis, viability and apoptosis. To the best of our knowledge, there are currently no studies suggesting the possible correlation between the expression of Merm1/Wbscr22 in tumor cells and chemosensitivity to antitumor agents. In the present study, two human non‑small cell lung cancer cell lines, H1299 and H460, were used to investigate whether Merm1/Wbscr22 affects chemosensitivity to antitumor agents, including cisplatin (CDDP), doxorubicin (ADM), paclitaxel (PTX), mitomycin (MMC), 7‑Ethyl‑10‑hydroxycamptothecin (SN‑38; the active metabolite of camptothecin) and 5‑fluorouracil (5‑FU). Merm1/Wbscr22 knockdown cell lines (H1299‑shRNA and H460‑shRNA) and negative control cell lines (H1299‑NC and H460‑NC) were established by stable transfection, and the efficiency of Merm1/Wbscr22 knockdown was confirmed by western blotting, immunofluorescence microscopy and quantitative polymerase chain reaction. The results demonstrated that shRNA‑mediated knockdown of Merm1/Wbscr22 did not affect cell proliferation in vitro and in vivo. The H460 cells harboring wild type p53 were markedly more sensitive to all six antitumor agents as compared with the p53‑null H1299 cells. Downregulation of Merm1/Wbscr22 did not affect H1299 sensitivity to any of the six antitumor agents, whereas attenuated H460 sensitivity to SN‑38 and 5‑FU, without significant alteration in p53 at both mRNA and protein levels, was identified. The reduced H460 sensitivity to SN‑38 was further confirmed in vivo. SN‑38 demonstrated significant tumor growth inhibitory activity in both H460 and H460‑NC tumor xenograft models, but only marginally suppressed the H460‑shRNA xenograft tumor growth. Furthermore, CDDP (4, 10, 15 µg/ml)‑resistant human non‑small lung cancer cells A549 (A549‑CDDPr‑4, 10, 15) expressed significant amounts of Merm1/Wbscr22 protein, as compared with the parental A549 cells. In conclusion, shRNA‑mediated knockdown of Merm1/Wbscr22 attenuates H460 sensitivity to SN‑38 and 5‑FU, suggesting Merm1/Wbscr22 is involved in chemosensitivity to SN‑38 and 5‑FU in H460 cells. No direct correlation between the p53 expression level and altered chemosensitivity was identified.

View Figures

View References

1	Pober BR: Williams-Beuren syndrome. New Engl J Med. 362:239–252. 2010. View Article : Google Scholar : PubMed/NCBI
2	Bellugi U, Lichtenberger L, Mills D, Galaburda A and Korenberg JR: Bridging cognition, the brain and molecular genetics: evidence from Williams syndrome. Trends Neurosci. 22:197–207. 1999. View Article : Google Scholar : PubMed/NCBI
3	Morris CA, Demsey SA, Leonard CO, Dilts C and Blackburn BL: Natural history of Williams syndrome: physical characteristics. J Pediatr. 113:318–326. 1988. View Article : Google Scholar : PubMed/NCBI
4	Merla G, Ucla C, Guipponi M and Reymond A: Identification of additional transcripts in the Williams-Beuren syndrome critical region. Hum Genet. 110:429–438. 2002. View Article : Google Scholar : PubMed/NCBI
5	Doll A and Grzeschik KH: Characterization of two novel genes, WBSCR20 and WBSCR22, deleted in Williams-Beuren syndrome. Cytogenet Cell Genet. 95:20–27. 2001. View Article : Google Scholar : PubMed/NCBI
6	Cheng X: DNA modification by methyltransferases. Curr Opin Struct Biol. 5:4–10. 1995. View Article : Google Scholar : PubMed/NCBI
7	Takebayashi S, Tamura T, Matsuoka C and Okano M: Major and essential role for the DNA methylation mark in mouse embryogenesis and stable association of DNMT1 with newly replicated regions. Mol Cell Biol. 27:8243–8258. 2007. View Article : Google Scholar : PubMed/NCBI
8	Nakazawa Y, Arai H and Fujita N: The novel metastasis promoter Merm1/Wbscr22 enhances tumor cell survival in the vasculature by suppressing Zac1/p53-dependent apoptosis. Cancer Res. 71:1146–1155. 2011. View Article : Google Scholar : PubMed/NCBI
9	Tiedemann RE, Zhu YX, Schmidt J, et al: Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res. 72:757–768. 2012. View Article : Google Scholar : PubMed/NCBI
10	Li H and Yang BB: Friend or foe: the role of microRNA in chemotherapy resistance. Acta Pharmacol Sin. 34:870–879. 2013. View Article : Google Scholar : PubMed/NCBI
11	Zhang X, Ding L and Sandford AJ: Selection of reference genes for gene expression studies in human neutrophils by real-time PCR. BMC Mol Biol. 6:42005. View Article : Google Scholar : PubMed/NCBI
12	Rho HW, Lee BC, Choi ES, et al: Identification of valid reference genes for gene expression studies of human stomach cancer by reverse transcription-qPCR. BMC Cancer. 10:2402010. View Article : Google Scholar : PubMed/NCBI
13	Weglarz L, Molin I, Orchel A, Parfiniewicz B and Dzierzewicz Z: Quantitative analysis of the level of p53 and p21(WAF1) mRNA in human colon cancer HT-29 cells treated with inositol hexaphosphate. Acta Bioch Pol. 53:349–356. 2006.PubMed/NCBI
14	Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936–942. 1987.PubMed/NCBI
15	Takahashi T, Nau MM, Chiba I, et al: p53: a frequent target for genetic abnormalities in lung cancer. Science. 246:491–494. 1989. View Article : Google Scholar : PubMed/NCBI
16	Lin DL and Chang C: p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily. J Biol Chem. 271:14649–14652. 1996. View Article : Google Scholar : PubMed/NCBI
17	Vermeulen PB, Gasparini G, Fox SB, et al: Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 38:1564–1579. 2002. View Article : Google Scholar : PubMed/NCBI
18	Hendrix MJ, Wood WR, Seftor EA, et al: Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res. 50:4121–4130. 1990.
19	Teng IW, Hou PC, Lee KD, et al: Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res. 71:4653–4663. 2011. View Article : Google Scholar : PubMed/NCBI
20	Kerr JF, Winterford CM and Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer. 73:2013–2026. 1994. View Article : Google Scholar : PubMed/NCBI
21	Bak Y, Kim H, Kang JW, et al: A synthetic naringenin derivative, 5-hydroxy-7,4′-diacetyloxyflavanone-N-phenyl hydrazone (N101-43), induces apoptosis through up-regulation of Fas/FasL expression and inhibition of PI3K/Akt signaling pathways in non-small-cell lung cancer cells. J Agric Food Chem. 59:10286–10297. 2011.PubMed/NCBI
22	Kim TH, Seo WD, Ryu HW, et al: Anti-tumor effects by a synthetic chalcone compound is mediated by c-Myc-mediated reactive oxygen species production. Chem Biol Interact. 188:111–118. 2010. View Article : Google Scholar : PubMed/NCBI
23	Rho JK, Choi YJ, Ryoo BY, et al: p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res. 67:1163–1169. 2007. View Article : Google Scholar : PubMed/NCBI
24	Lai SL, Perng RP and Hwang J: p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci. 7:64–70. 2000. View Article : Google Scholar : PubMed/NCBI
25	Kawasaki M, Nakanishi Y, Kuwano K, et al: The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res. 3:1195–1200. 1997.PubMed/NCBI
26	Kawasaki M, Nakanishi Y, Kuwano K, et al: Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer. 34:1352–1357. 1998. View Article : Google Scholar : PubMed/NCBI
27	Osaki M, Tatebe S, Goto A, et al: 5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: role of the p53 gene. Apoptosis. 2:221–226. 1997. View Article : Google Scholar : PubMed/NCBI
28	Li YX, Lin ZB and Tan HR: Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells. Acta Pharmacol Sin. 25:76–82. 2004.PubMed/NCBI
29	Yu ZW, Zhao P, Liu M, et al: Reversal of 5-flouroucial resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells. World J Gastroenterol. 10:1979–1983. 2004.PubMed/NCBI
30	Liu HC, Chen GG, Vlantis AC, et al: 5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. Cancer J. 12:482–493. 2006. View Article : Google Scholar : PubMed/NCBI
31	Liu Y, Xing H, Weng D, et al: Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer. Cancer Lett. 274:47–53. 2009. View Article : Google Scholar : PubMed/NCBI
32	Takeba Y, Sekine S, Kumai T, et al: Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol Pharm Bull. 30:1400–1406. 2007. View Article : Google Scholar
33	Takeba Y, Kumai T, Matsumoto N, et al: Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J Pharmacol Sci. 104:232–242. 2007. View Article : Google Scholar : PubMed/NCBI
34	Vaziri SA, Hill J, Chikamori K, et al: Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin. Mol Cancer Ther. 4:1880–1890. 2005. View Article : Google Scholar : PubMed/NCBI
35	Ueno M, Nonaka S, Yamazaki R, Deguchi N and Murai M: SN-38 induces cell cycle arrest and apoptosis in human testicular cancer. Eur Urol. 42:390–397. 2002. View Article : Google Scholar : PubMed/NCBI
36	Xie X, Sasai K, Shibuya K, et al: P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative. Cancer Chemother Pharmacol. 45:362–368. 2000. View Article : Google Scholar : PubMed/NCBI
37	Osaki S, Nakanishi Y, Takayama K, et al: Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells. Cancer Gene Ther. 7:300–307. 2000. View Article : Google Scholar : PubMed/NCBI
38	Boyer J, McLean EG, Aroori S, et al: Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res. 10:2158–2167. 2004. View Article : Google Scholar : PubMed/NCBI
39	Oizumi S, Isobe H, Ogura S, et al: Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells. Anticancer Res. 22:4029–4037. 2002.PubMed/NCBI
40	McDonald AC and Brown R: Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Br J Cancer. 78:745–751. 1998. View Article : Google Scholar : PubMed/NCBI
41	Wang Y, Zhu S, Cloughesy TF, Liau LM and Mischel PS: p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene. 23:1283–1290. 2004. View Article : Google Scholar : PubMed/NCBI